Beyond humanization and de-immunization: Tolerization as a method for reducing the immunogenicity of biologics

Expert Review of Clinical Pharmacology

Volumn 6, Issue 6, 2013, Pages 651-662

  De Groot, Anne S ^a,b   Terry, Frances ^b   Cousens, Leslie ^b   Martin, William ^b  

^a UNIVERSITY OF RHODE ISLAND   (United States)

^b EpiVax Inc   (United States)

Author keywords

alemtuzumab; bio better; biologic; biosimilar; Campath ; immunogenicity; mAb; monoclonal; quality by design; tolerance; tregitope

Indexed keywords

ALEMTUZUMAB; BOTULINUM TOXIN A; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPITOPE; GLUCAN 1,4 ALPHA GLUCOSIDASE; LYSOSTAPHIN; RITUXIMAB; STAPHYLOKINASE;

AMINO ACID SEQUENCE; ANTIBODY ENGINEERING; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; CELL CULTURE; CELL EXPANSION; CELL GROWTH; CELLULAR IMMUNITY; CHRONIC LYMPHATIC LEUKEMIA; CYTOKINE PRODUCTION; DEHUMANIZATION; ENZYME REPLACEMENT; EPITOPE MAPPING; FEASIBILITY STUDY; FOOD AND DRUG ADMINISTRATION; GLYCOGEN STORAGE DISEASE TYPE 2; HEAVY CHAIN; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; MEMORY T LYMPHOCYTE; MULTIPLE SCLEROSIS; OBSERVATIONAL STUDY; POINT MUTATION; PROSPECTIVE STUDY; PROTEIN ENGINEERING; PROTEIN EXPRESSION; PROTEIN STABILITY; REGULATORY T LYMPHOCYTE; RETROSPECTIVE STUDY; REVIEW; SEQUENCE HOMOLOGY; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; VALIDATION STUDY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; BIOLOGICAL PRODUCTS; EPITOPES, T-LYMPHOCYTE; HUMANS;

EID: 84887283047     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/17512433.2013.835698     Document Type: Review

References (86)

1. Moise L, Song C, Martin WD, Tassone R, De Groot AS, Scott DW. Effect of HLA DR epitope de-immunizaton of Factor VIII in vitro and in vivo. Clin. Immunol. 142(3), 320-331 (2012).
2. Collen D, Lijnen HR. Thrombolytic agents. Thromb. Haemost. 93(4), 627-630 (2005).
3. Joseph A, Munroe K, Housman M, Garman R, Richards S. Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease model. Clin. Exp. Immunol. 152(1), 138-146 (2008).
4. Messinger YH, Mendelsohn NJ, Rhead W et al. Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease. Genet. Med. 14(1), 135-142 (2012).
5. Kubisz P, Plamenová I, Hollý P, Stasko J. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy. Med. Sci. Monit. 15(6), CS105-CS111 (2009).
6. Waldmann H. A personal history of the CAMPATH-1H antibody. Med. Oncol. 19 (Suppl.), S3-S9 (2002).
7. Lefranc MP, Ehrenmann F, Ginestoux C, Giudicelli V, Duroux P. Use of IMGT(-) databases and tools for antibody engineering and humanization. Methods Mol. Biol. 907, 3-37 (2012).
8. Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat. Rev. Drug Discov. 9(10), 767-774 (2010).
9. Laffleur B, Pascal V, Sirac C, Cogné M. Production of human or humanized antibodies in mice. Methods Mol. Biol. 901, 149-159 (2012).
10. Clark M. Antibody humanization: a case of the 'Emperor's new clothes'? Immunol. Today 21(8), 397-402 (2000).
11. De Groot AS, Moise L, McMurry JA et al. Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes". Blood 112(8), 3303-3311 (2008).
12. De Groot AS, Martin W. Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics. Clin. Immunol. 131(2), 189-201 (2009).
13. Su Y, Rossi R, De Groot AS, Scott DW. Regulatory T cell epitopes (Tregitopes) in IgG induce tolerance in vivo and lack immunogenicity per se. J. Leukoc. Biol. 94(2), 377-383 (2013).
14. Cousens LP, Najafian N, Mingozzi F et al. In vitro and in vivo studies of IgG-derived Treg epitopes (Tregitopes): A promising new tool for tolerance induction and treatment of autoimmunity. J. Clin. Immunol. 33(1), 43-49 (2013).
15. Harding FA, Stickler MM, Razo J, DuBridge RB. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. mAbs. 2(3), 256-265 (2010).
16. McIntyre JA, Kincade M, Higgins NG. Detection of IGA anti-OKT3 antibodies in OKT3-treated transplant recipients. Transplantation 61(10), 1465-1469 (1996).
17. Uckun FM, Messinger Y, Chen CL et al. Treatment of therapy-refractory B-lineage acute lymphoblastic leukemia with an apoptosis-inducing CD19-directed tyrosine kinase inhibitor. Clin. Cancer Res. 5(12), 3906-3913 (1999).
18. Kaminski MS, Zelenetz AD, Press OW et al . Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J. Clin. Oncol. 19(19), 3918-3928 (2001).
19. Stroomer JW, Roos JC, Sproll M et al. Safety and biodistribution of 99mTechnetium-labeled anti- CD44v6 monoclonal antibody BIWA 1 in head and neck cancer patients. Clin. Cancer Res. 6(8), 3046-3055 (2000).
20. Davis TA, Grillo-López AJ, White CA et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J. Clin. Oncol. 18(17), 3135-3143 (2000).
21. Piro LD, White CA, Grillo-López AJ et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann. Oncol. 10(6), 655-661 (1999).
22. Pijpe J, van Imhoff GW, Spijkervet FK et al. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. Arthritis Rheum. 52(9), 2740-2750 (2005).
23. Looney RJ, Anolik JH, Campbell D et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 50(8), 2580-2589 (2004).
24. M Kim JH, Hong HJ. Humanization by CDR grafting and specificity- determining residue grafting. Methods Mol. Biol. 907, 237-245 (2012).
25. Rosenberg AS. Immunogenicity of biological therapeutics: a hierarchy of concerns. Dev. Biol. (Basel) 112, 15-21 (2003).
26. Barbosa MD. Immunogenicity of biotherapeutics in the context of developing biosimilars and biobetters. Drug Discov. Today 16, 345-353 (2011).
27. Eser A, Primas C, Reinisch W. Drug monitoring of biologics in inflammatory bowel disease. Curr. Opin. Gastroenterol. 29(4), 391-396 (2013).
28. Shankar G, Pendley C, Stein KE. A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat. Biotechnol. 25, 555-561 (2007).
29. Haselbeck A. Epoetins: differences and their relevance to immunogenicity. Curr. Med. Res. Opin. 19(5), 430-432 (2003).
30. Eckardt KU, Casadevall N. Pure red-cell aplasia due to anti-erythropoietin antibodies. Nephrol. Dial. Transplant 18, 865-869 (2003).
31. Haribhai D, Engle D, Meyer M et al. A threshold for central T cell tolerance to an inducible serum 870 protein. J. Immunol. 170(6), 3007-3014 (2003).
32. Mendelsohn NJ, Messinger YH, Rosenberg AS, Kishnani PS. Elimination of antibodies to recombinant enzyme in pompe's disease. N. Engl. J. Med. 360(2), 194-195 (2009).
33. Garman RD, Munroe K, Richards SM. Methotrexate reduces antibody responses to recombinant human alpha-galactosidase A therapy in a mouse model of Fabry disease. Clin. Exp. Immunol. 137(3), 496-502 (2004).
34. Wullner D, Zhou L, Bramhall E et al. Considerations for optimization and validation of an in vitro PBMC derived T cell assay for immunogenicity prediction of biotherapeutics. Clin. Immunol. 137(1), 5-14 (2010).
35. Barbosa MD, Vielmetter J, Chu S, Smith DD, Jacinto J. Clinical link between MHC class II haplotype and interferon-beta (IFN-beta) immunogenicity. Clin. Immunol. 118, 42-50 (2006).
36. Jawa V, Cousens LP, Awwad M, Wakshull E, Kropshofer H, De Groot AS. T-cell dependent immunogenicity of protein therapeutics: preclinical assessment and mitigation. Clinical Immunology. (In Press).
37. Wang P, Sidney J, Dow C, Mothé B, Sette A, Peters B. A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLoS Comput. Biol. 4(4), e1000048 (2008).
38. Koren E, De Groot AS, Jawa V et al. Clinical validation of the "in silico" prediction of immunogenicity of a human recombinant therapeutic protein. Clin. Immunol. 124(1), 25-32 (2007).
39. Cohen T, Moise L, Ardito M, Martin W, De Groot AS. A method for individualizing the prediction of immunogenicity of protein vaccines and biologic therapeutics: individualized T cell epitope measure (iTEM). J. Biomed. Biotechnol. 7 (2010).
40. Tatarewicz SM, Wei X, Gupta S, Masterman D, Swanson SJ, Moxness MS. Development of a maturing T-cell-mediated immune response in patients with idiopathic Parkinson's disease receiving r-metHuGDNF via continuous intraputaminal infusion. J. Clin. Immunol. 27(6), 620-627 (2007).
41. Jawa V, Cousens LP, De Groot AS. Immunogenicity of therapeutic fusion proteins: contributory factors and clinical experience. fusion protein technologies for biopharmaceuticals: Applications and Challenges (1st Edition). Schmidt SR (Ed.). John Wiley & Sons, Inc. (2013).
42. Kast WM, Brandt RM, Sidney J et al. Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J. Immunol. 152, 3904-3912 (1994).
43. Schafer JR, Jesdale BM, George JA, Kouttab NM, De Groot AS. Prediction of well-conserved HIV-1 ligands using a matrix-based algorithm, EpiMatrix. Vaccine 16(19), 1880-1884 (1998).
44. De Groot AS, Bosma A, Chinai N et al. From genome to vaccine: in silico predictions, ex vivo verification. Vaccine 19(31), 4385-4395 (2001).
45. De Groot AS, Saint-Aubin C, Bosma A, Sbai H, Rayner J, Martin W. Rapid determination of HLA B07 ligands from the West Nile virus NY99 genome. Emerg. Infect. Dis. 7(4), 706-713 (2001).
46. Moutaftsi M, Peters B, Pasquetto V et al. A consensus epitope prediction approach identifies the breadth of murine T(CD8+)- cell responses to vaccinia virus. Nat. Biotechnol. 24(7), 817-819 (2006).
47. Collen D, Bernaerts R, Declerck P et al. Recombinant staphylokinase variants with altered immunoreactivity. I: Construction and characterization. Circulation 94(2), 197-206 (1996).
48. Parker AS, Choi Y, Griswold KE, Bailey-Kellogg C. Structure-guided deimmunization of therapeutic proteins. J. Comput. Biol. 20(2), 152-165 (2013).
49. Jones TD, Crompton LJ, Carr FJ, Baker MP. Deimmunization of monoclonal antibodies. Methods Mol. Biol. 525, 405-423 (2009).
50. De Groot AS, Knopf PM, Martin W. De-immunization of therapeutic proteins by T-cell epitope modification. Dev. Biol. (Basel) 122, 171-194 (2005).
51. Cousens L, Moise L, Terry F, Martin W, De Groot AS. Immunogenic biologics: validation of screening, deimmunization and tolerization approaches (P3251). J. Immunol. 190, 192 (2013).
52. Celis E, Ou D, Otvos Jr L. Recognition of hepatitis B surface antigen by human T lymphocytes. Proliferative and cytotoxic responses to a major antigenic determinant defined by synthetic peptides. J. Immunol. 140, 1808-1815 (1998).
53. Scanlan MJ, Jager D. Challenges to the development of antigen-specific breast cancer vaccines. Breast Cancer Res. 3(2), 95-98 (2001).
54. Mullbacher A. Viral escape from immune recognition: multiple strategies of adenoviruses. Immunol. Cell Biol. 70(Pt 1), 59-63 (1992).
55. Hill AV, Jepson A, Plebanski M, Gilbert SC. Genetic analysis of host-parasite coevolution in human malaria. Philos. Trans. R. Soc. Lond. B Biol. Sci. 352(1359), 1317-1325 (1997).
56. Vossen MT, Westerhout EM, Soderberg-Naucler C, Wiertz EJ. Viral immune evasion: a masterpiece of evolution. Immunogenetics 54(8), 527-542 (2002).
57. Jones TD, Phillips WJ, Smith BJ et al. Identification and removal of a promiscuous CD4+ T cell epitope from the C1 domain of factor VIII. J. Thromb. Haemost. 3, 991-1000 (2005).
58. Gilles JG, Lavend'homme R, Peerlinck K et al. Some factor VIII (FVIII) inhibitors recognise a FVIII epitope(s) that is present only on FVIII-vWF complexes. Thromb. Haemost. 82, 40-45 (1999).
59. Hellendoorn K, Jones T, Watkins J, Baker M, Hamilton A, Carr F. Limiting the risk of immunogenicity by identification and removal of T-cell epitopes (DeImmunisation). Association for Immunotherapy of Cancer: Cancer Immunotherapy-2nd Annual Meeting Mainz, Germany. Cancer Cell Int. 4(Suppl. 1), S20 (2004).
60. Tangri S, Mothe BR, Eisenbraun J et al. Rationally engineered therapeutic proteins with reduced immunogenicity. J. Immunol. 174(6), 3187-3196 (2005).
61. Yeung VP, Chang J, Miller J, Barnett C, Stickler M, Harding FA. Elimination of an immunodominant CD4+ T cell epitope in human IFN-beta does not result in an in vivo response directed at the subdominant epitope. J. Immunol. 172(11), 6658-6665 (2004).
62. Warmerdam PA, Plaisance S, Vanderlick K et al. Elimination of a human T-cell region in staphylokinase by T-cell screening and computer modeling. Thromb. Haemost. 87(4), 666-673 (2002).
63. Parker AS, Choi Y, Griswold KE, Bailey-Kellogg C. Structure-guided de immunization of therapeutic proteins. J. Comput. Biol. 20(2), 152-165 (2013).
64. Moise L, Gutierrez AH, Bailey-Kellogg C et al. The two-faced T cell epitope: examining the host-microbe interface with JanusMatrix. Hum. Vaccin. Immunother. 9(7), 1577-1586 (2012).
65. Cousens LP, Su Y, McClaine E et al. Application of IgG-derived natural Treg epitopes (IgG Tregitopes) to antigen-specific tolerance induction in a murine model of type 1 diabetes. J. Diabetes Res. 621693 (2013).
66. Hui DJ, Basner-Tschakarjan E, Chen Y et al. Modulation of CD8+ T cell responses to AAV vectors with IgG-derived MHC class II epitopes. Mol. Ther. doi:10.1038/ mt.2013.166 (2013) (Epub ahead of print).
67. Cousens LP, Tassone R, Mazer BD, Ramachandiran V, Scott DW, De Groot AS. Tregitope update: mechanism of action parallels IVIg. Autoimmun. Rev. 12(3), 436-443 (2012).
68. Schuster SJ, Neelapu SS, Gause BL et al. Vaccination with patient-specific tumorderived antigen in first remission improves disease-free survival in follicular lymphoma. J. Clin. Oncol. 29(20), 2787-2794 (2011).
69. Ephrem A, Chamat S, Miquel C et al. Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood 111(2), 715-722 (2008).
70. Tsurikisawa N, Saito H, Oshikata C, Tsuburai T, Akiyama K. High-dose intravenous immunoglobulin treatment increases regulatory T cells in patients with eosinophilic granulomatosis with polyangiitis. J. Rheumatol. 39(5), 1019-1025 (2012).
71. Lopez M, Clarkson MR, Albin M, Sayegh MH, Najafian N. A novel mechanism of action for anti-thymocyte globulin: induction of CD4+CD25+Foxp3+ regulatory T cells. J. Am. Soc. Nephrol. 17(10), 2844-2853 (2006).
72. Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat. Rev. Immunol. 13(3), 176-89 (2013).
73. Mingozzi F, High KA. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood 122(1), 23-36 (2013).
74. Adair P, Su Y, Scott DW. Tolerance induction in hemophilia A animal models: battling inhibitors with antigen-specific immunotherapies. Discov. Med. 15(84), 275-282 (2013).
75. Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat. Rev. Immunol. 3, 253-257 (2003).
76. Bakacs T, Mehrishi JN, Szabo M, Moss RW. Interesting possibilities to improve the safety and efficacy of ipilimumab (Yervoy). Pharmacol. Res. 66(2), 192-197 (2012).
77. Baxevanis CN, Ioannides CG, Reclos GJ, Papamichail M. Evidence for distinct epitopes on human IgG with T cell proliferative and suppressor function. Eur. J. Immunol. 16, 1013-1016 (1986).
78. Zambidis ET, Scott DW. Epitope-specific tolerance induction with an engineered immunoglobulin. Proc. Natl Acad. Sci. U.S. A. 93, 5019-5024 (1996).
79. Vicente A, Barreto M, Demengeot J, Fesel C. Genetic factors in systemic lupus erythematosus. Instituto Gulbenkian de Ciência. Annual report Lisbon, Portugal (2005).
80. Bystryn JC, Jiao D. IVIg selectively and rapidly decreases circulating pathogenic autoantibodies in pemphigus vulgaris. Autoimmunity 39(70), 601-607 (2006).
81. Jordan SC, Vo AA, Peng A, Toyoda M, Tyan D. Intravenous gammaglobulin (IVIG): a novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients. Am. J. Transplant. 6(3), 459-466 (2006).
82. Coles AJ. Alemtuzumab treatment of multiple sclerosis. Semin. Neurol. 33(1), 66-73 (2013).
83. Somerfield J, Hill-Cawthorne GA, Lin A et al. A novel strategy to reduce the immunogenicity of biological therapies. J. Immunol. 185(1), 763-768 (2010).
84. Isaacs JD, Watts RA, Hazleman BL et al. Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet 340(8822), 748-752 (1992).
85. Isaacs JD, Manna VK, Rapson N et al. CAMPATH-1H in rheumatoid arthritis: an intravenous dose-ranging study. Br. J. Rheumatol. 35(3), 231-240 (1996).
86. Matteson EL, Yocum DE, St Clair EW et al. Treatment of active refractory rheumatoid arthritis with humanized monoclonal antibody CAMPATH-1H administered by daily subcutaneous injection. Arthritis Rheum. 38(9), 1187-1193 (1995).